Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by FarmerBettyon Oct 05, 2022 4:38pm
92 Views
Post# 35007769

RE:RE:RC New Ceo

RE:RE:RC New CeoYes, blogged when they were on the scene but never them pumped like you did. Now you say the same thing about this Ceo this is the credibility we have been lacking forever. 

Why are you dodging the second question about the world class science with no deals?

The BOD of directors is no longer in control it is the Boston Group.

Look back at Boston group PP last August 2021. Purpose for filing PMN 310 IND, expand portfolio of antibodies and patents. What have you seen for an expansion of new antibodies or  new patents? No new patents. Remember Promis said in their corporate updates not long ago their technology could discover new protein targets in a matter of weeks?  What about in that August 2021 PR to establish a discovery lab in the Boston area? Mention of a discovery lab was made mention of in Aug 15, 2022 PR. Do they have a new lab in the Boston area and if, is this not news worthy a new lab has been opened? What about the grant they recieved for a vaccine, can't say how much? Just being played.
<< Previous
Bullboard Posts
Next >>